Skip to main content

New Products: DVS Sciences, Biognosys

Premium

DVS Sciences this week introduced its CyTOF 2 Mass Cytometer instrument, an updated version of its original CyTOF mass cytometer. The company also introduced new MaxPar Panel Kits for use with the instrument.

The CyTOF 2 has the ability to simultaneously measure up to 120 biomarkers in single cells at a rate of 1,000 cells per second, the company said.


Biognosys this week launched its SkinDig100 assay panel for the quantification of 100 proteins in human skin biopsies and keratinocyte cell culture samples.

The panel uses multiple-reaction monitoring mass spec to quantify the proteins, which represent functional areas including differentiation, oxidative stress response, apoptosis inhibition as well as many other areas relevant to skin metabolism and a wide range of diseases, the company said.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.